Use of an ophthalmic formulation of megestrol acetate for the treatment of eosinophilic keratitis in cats.

OBJECTIVE

To evaluate a compounded ophthalmic formulation of 0.5% megestrol acetate to treat eosinophilic keratitis in cats.

STUDY DESIGN

Prospective study.

ANIMALS STUDIED

Seventeen client owned cats with eosinophilic keratitis in one or both eyes.

METHODS

Eosinophilic keratitis was confirmed by cytology. At each visit, fluorescein staining and photography were performed. Cats were initially treated q 8-12 h with 0.5% megestrol acetate in an aqueous base. Serum glucose was measured at the first or second reexamination.

RESULTS

Fifteen of 17 (88%) cats had a positive response to treatment, with 6 of 17 (35%) having complete resolution at the first reexamination (2-4 weeks). Two of 17 (12%) cats did not respond to treatment. Most cats required a treatment frequency of once daily to once weekly to maintain remission of disease. No ocular irritation or systemic side effects were noted in any cat.

CONCLUSIONS AND CLINICAL RELEVANCE

The use of an ophthalmic formulation of 0.5% megestrol acetate is a viable option for treating feline eosinophilic keratitis.